Research and Markets: Psoriasis – Thought Leader Panel 2012 – A Summary of Persepectives from 6 Key Opinion Leaders

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/2r4sgn/psoriasis_thought) has announced the addition of the "Psoriasis Thought Leader Panel #22 2012-04" report to their offering.

Psoriasis Thought Leader Panel #22 summarizes the perspectives of 6 key opinion leaders who had attended Gene to Clinic (London), AAD, or both in 1Q2012, supplemented with comments from Panel #21 and publicly available data on key drugs in development.

The Panel Weighs in On:

- The pros and cons of sequencing IL23, IL17, JAK, other orals and topicals against their established 1st line biologicals.

- Increases and decreases in cardiovascular events associated with inhibitors of TNF, IL23, IL17 and IL12.

- Advantages/disadvantages of IL23/IL12 vs p19 inhibitors.

- Advantages of a pure IL12 inhibitor

- Advantages/drawbacks for broad vs subreceptor selective IL17 approaches.

- Combinations and immunosuppression

More:
Research and Markets: Psoriasis - Thought Leader Panel 2012 - A Summary of Persepectives from 6 Key Opinion Leaders